henry schein inc. - HSIC
HSIC
Close Chg Chg %
73.73 0.04 0.05%
Closed Market
73.77
+0.04 (0.05%)
Volume: 1.57M
Last Updated:
Nov 21, 2024, 4:00 PM EDT
Company Overview: henry schein inc. - HSIC
HSIC Key Data
| Open $73.60 | Day Range 71.98 - 73.97 |
| 52 Week Range 63.69 - 82.63 | Market Cap $9.19B |
| Shares Outstanding 124.68M | Public Float 123.01M |
| Beta 0.87 | Rev. Per Employee N/A |
| P/E Ratio 30.19 | EPS $2.46 |
| Yield 0.00% | Dividend $17.22 |
| EX-DIVIDEND DATE Feb 8, 2019 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.86M |
HSIC Performance
| 1 Week | 7.29% | ||
| 1 Month | 5.39% | ||
| 3 Months | 4.17% | ||
| 1 Year | 5.88% | ||
| 5 Years | 6.45% |
HSIC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
14
Full Ratings ➔
About henry schein inc. - HSIC
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.
HSIC At a Glance
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
| Phone | 1-631-843-5500 | Revenue | 12.34B | |
| Industry | Medical Distributors | Net Income | 416.00M | |
| Sector | Distribution Services | Employees | 25,000 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
HSIC Valuation
| P/E Current | 30.194 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.978 |
| Price to Sales Ratio | 0.808 |
| Price to Book Ratio | 2.677 |
| Price to Cash Flow Ratio | 19.949 |
| Enterprise Value to EBITDA | 14.597 |
| Enterprise Value to Sales | 1.138 |
| Total Debt to Enterprise Value | 0.195 |
HSIC Efficiency
| Revenue/Employee | 493,560.00 |
| Income Per Employee | 16,640.00 |
| Receivables Turnover | 6.623 |
| Total Asset Turnover | 1.287 |
HSIC Liquidity
| Current Ratio | 1.673 |
| Quick Ratio | 0.996 |
| Cash Ratio | 0.064 |
HSIC Profitability
| Gross Margin | 29.589 |
| Operating Margin | 5.787 |
| Pretax Margin | 4.393 |
| Net Margin | 3.371 |
| Return on Assets | 4.338 |
| Return on Equity | 11.717 |
| Return on Total Capital | 6.504 |
| Return on Invested Capital | 7.803 |
HSIC Capital Structure
| Total Debt to Total Equity | 74.993 |
| Total Debt to Total Capital | 42.855 |
| Total Debt to Total Assets | 25.925 |
| Long-Term Debt to Equity | 61.477 |
| Long-Term Debt to Total Capital | 35.131 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Henry Schein Inc. - HSIC
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 10.12B | 12.40B | 12.65B | 12.34B | |
Sales Growth
| +1.34% | +22.55% | +1.98% | -2.44% | |
Cost of Goods Sold (COGS) incl D&A
| 7.30B | 8.73B | 9.00B | 8.69B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 185.54M | 209.53M | 212.00M | 248.00M | |
Depreciation
| 64.30M | 70.40M | 68.00M | 70.00M | |
Amortization of Intangibles
| 121.24M | 139.13M | 144.00M | 178.00M | |
COGS Growth
| +5.94% | +19.49% | +3.08% | -3.45% | |
Gross Income
| 2.81B | 3.67B | 3.65B | 3.65B | |
Gross Income Growth
| -8.95% | +30.48% | -0.63% | +0.05% | |
Gross Profit Margin
| +27.81% | +29.61% | +28.85% | +29.59% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.25B | 2.82B | 2.71B | 2.94B | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 2.25B | 2.82B | 2.71B | 2.94B | |
SGA Growth
| -4.71% | +25.39% | -3.78% | +8.34% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 32.09M | 3.15M | 191.00M | 126.00M | |
EBIT after Unusual Expense
| 535.30M | 851.66M | 747.00M | 588.00M | |
Non Operating Income/Expense
| 5.97M | 6.49M | 18.00M | 41.00M | |
Non-Operating Interest Income
| 9.84M | 6.45M | 17.00M | 17.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 41.38M | 27.60M | 44.00M | 87.00M | |
Interest Expense Growth
| -18.54% | -33.30% | +59.42% | +97.73% | |
Gross Interest Expense
| 41.38M | 27.60M | 44.00M | 87.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 499.89M | 830.55M | 721.00M | 542.00M | |
Pretax Income Growth
| -26.52% | +66.14% | -13.19% | -24.83% | |
Pretax Margin
| +4.94% | +6.70% | +5.70% | +4.39% | |
Income Tax
| 95.37M | 197.35M | 170.00M | 120.00M | |
Income Tax - Current - Domestic
| 107.55M | 165.58M | 199.00M | 100.00M | |
Income Tax - Current - Foreign
| 40.80M | 42.75M | 44.00M | 40.00M | |
Income Tax - Deferred - Domestic
| (22.92M) | (14.68M) | (61.00M) | 6.00M | |
Income Tax - Deferred - Foreign
| (30.06M) | 3.70M | (12.00M) | (26.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 416.87M | 653.21M | 566.00M | 436.00M | |
Minority Interest Expense
| 15.63M | 29.29M | 28.00M | 20.00M | |
Net Income
| 401.24M | 623.91M | 538.00M | 416.00M | |
Net Income Growth
| -21.93% | +55.50% | -13.77% | -22.68% | |
Net Margin Growth
| +3.97% | +5.03% | +4.25% | +3.37% | |
Extraordinaries & Discontinued Operations
| - | - | - | 986.00K | - |
Discontinued Operations
| - | - | - | 986.00K | - |
Net Income After Extraordinaries
| 402.22M | 623.91M | 538.00M | 416.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 402.22M | 623.91M | 538.00M | 416.00M | |
EPS (Basic)
| 2.8225 | 4.4536 | 3.954 | 3.1848 | |
EPS (Basic) Growth
| -17.86% | +57.79% | -11.22% | -19.45% | |
Basic Shares Outstanding
| 142.50M | 140.09M | 136.06M | 130.62M | |
EPS (Diluted)
| 2.8048 | 4.4008 | 3.9055 | 3.1575 | |
EPS (Diluted) Growth
| -17.59% | +56.90% | -11.25% | -19.15% | |
Diluted Shares Outstanding
| 143.40M | 141.77M | 137.76M | 131.75M | |
EBITDA
| 752.93M | 1.06B | 1.15B | 962.00M | |
EBITDA Growth
| -17.97% | +41.36% | +8.05% | -16.35% | |
EBITDA Margin
| +7.44% | +8.58% | +9.09% | +7.80% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 75.00 | |
| Number of Ratings | 14 | Current Quarters Estimate | 1.229 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 4.776 | |
| Last Quarter’s Earnings | 1.22 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.50 | Next Fiscal Year Estimate | 5.208 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 11 | 13 | 13 |
| Mean Estimate | 1.23 | 1.19 | 4.78 | 5.21 |
| High Estimates | 1.26 | 1.25 | 4.81 | 5.42 |
| Low Estimate | 1.19 | 1.12 | 4.72 | 5.05 |
| Coefficient of Variance | 1.80 | 3.11 | 0.49 | 2.16 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 4 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 6 | 6 | 7 |
| UNDERWEIGHT | 2 | 2 | 1 |
| SELL | 1 | 1 | 1 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Henry Schein Inc. - HSIC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Henry Schein Inc. - HSIC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 12, 2024 | Anne H. Margulies Director | 19,570 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $68.51 per share | 1,340,740.70 |
| May 16, 2024 | Stanley M. Bergman Chairman, CEO; Director | 476,356 | Bona fide gift | 0.00 |
| Mar 20, 2024 | James P. Breslawski Vice Chairman, President; Director | 209,562 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $74.37 per share | 15,585,125.94 |
| Mar 12, 2024 | Michael Saul Ettinger EVP & Chief Operating Officer | 100,091 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 12, 2024 | Mark E. Mlotek EVP, Chief Strategic Officer; Director | 90,851 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 12, 2024 | Bradford C. Connett CEO, NA Distribution Group | 79,538 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 12, 2024 | Ronald N. South SVP & Chief Financial Officer | 69,933 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2024 | Philip A. Laskaway Director | 24,565 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $76.29 per share | 1,874,063.85 |
| Mar 6, 2024 | Walter Siegel Sr. VP & Chief Legal Officer | 43,660 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Steven Paladino Director | 136,163 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.88 per share | 10,468,211.44 |
| Mar 6, 2024 | James P. Breslawski Vice Chairman, President; Director | 212,469 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $76.5 per share | 16,253,878.50 |
| Mar 6, 2024 | Joseph L. Herring Director | 24,904 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Lorelei McGlynn SVP, Chief Human Res. Officer | 92,868 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Lorelei McGlynn SVP, Chief Human Res. Officer | 80,302 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.88 per share | 6,173,617.76 |
| Mar 6, 2024 | Kurt P. Kuehn Director | 16,202 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Kurt P. Kuehn Director | 13,598 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $77.07 per share | 1,047,997.86 |
| Mar 6, 2024 | Scott Serota Director | 5,941 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Bradley T. Sheares Director | 42,774 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Bradley T. Sheares Director | 40,170 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.88 per share | 3,088,269.60 |
| Mar 6, 2024 | Deborah M. Derby Director | 9,672 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |